AstraZeneca scraps oral GLP-1 after PhI ‘does not meet that ambition’ of trumping the competition
As the competition heats up in the GLP-1 space, some are bound to get out and find other ways of delivering diabetes and obesity drugs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
